PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.375
Bid: 7.25
Ask: 7.50
Change: 0.00 (0.00%)
Spread: 0.25 (3.448%)
Open: 7.375
High: 7.375
Low: 7.375
Prev. Close: 7.375
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IXICO plc announces SBRI Healthcare contract

16 Apr 2014 07:00

RNS Number : 9231E
IXICO plc
16 April 2014
 



16 April 2014

 

 

IXICO plc announces SBRI Healthcare development contract

 

IXICO plc (Ticker: IXI) ("IXICO" or the "Company"), the brain health company, announces that it has been awarded a development contract by SBRI Healthcare (The Small Business Research Initiative for Healthcare) to cover Phase 1 funding for the development of an online application designed to support dementia sufferers post-diagnosis.

Receiving a dementia diagnosis is inevitably traumatic for patients and far too often, patients and their families receive very little support until there is a crisis. This development project will build on Assessa™, IXICO's digital healthcare platform to support dementia diagnosis, to address post-diagnostic care planning and support. It aims to harness web and mobile technologies to provide ongoing support and to assist those living with dementia as well as their families, carers and healthcare professionals. The goal is to prolong and enhance independent living by facilitating improved self-care with full interaction with the relevant healthcare professionals and other support agencies. Social media concepts will be adapted to build a personal management tool whereby diagnosis is carefully linked to continuing care-planning and support. This will then aid the transition into other care settings by travelling with the patient and relatives throughout the course of the illness.

The project will be led by IXICO in partnership with the Health Innovation Network South London. (www.hin-southlondon.org)

Commenting on the award, Derek Hill, CEO of IXICO said:

 

'We are delighted to receive this support from SBRI Healthcare which will help us to extend the potential patient benefit of Assessa™ following diagnosis and is central to the widening of our digital healthcare offering. We look forward to working with the Health Innovation Network to improve the care of dementia sufferers.'

 

Commenting on the award, Dr Hugo DeWaal, Clinical Director for Dementia at the Health Innovation Network said:

 

'Dementia is a key health and social care priority, and the Health Innovation Network is keen to develop a tool that is helpful for people with dementia, their families and carers. We hope that this partnership and SBRI funding will allow us to rapidly improve dementia care for a greater number of people.'

About SBRI Healthcare

The Small Business Research Initiative for Healthcare (SBRI Healthcare) is an NHS England initiative, championed by the newly formed Academic Health Science Networks (AHSNs), that aim to promote UK economic growth whilst addressing unmet health needs and enhancing the take up of known best practice. Part of Innovation Health and Wealth, the SBRI Healthcare programme sets industry the challenge in a series of health related competitions which result in fully funded development contracts between the awarded company and the NHS. Unlike many R&D projects which offer grant or match funding, SBRI contracts are 100 per cent funded and the company retains the IP.

More information is available on www.sbrihealthcare.co.uk

About IXICO

IXICO, the brain health company, was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase 0-III) and experimental medicine markets and more recently launched into the wider clinical diagnostic market. Since incorporation, IXICO has been awarded contracts by nine of the top 15 global pharmaceutical companies as well as leading biotechnology companies. In October 2013, IXICO plc was admitted to trading on AIM. More information is available on www.ixico.com

About the Health Innovation Network

The Health Innovation Network is a membership organisation, driving lasting improvements in health and wellbeing across South London by sharing innovations across the health system and capitalising on teaching and research strengths. Founded by NHS England, the Health Innovation Network is the Academic Health Science Network (AHSN) for South London. We are focusing on health priorities for our local communities across a number of clinical areas and cross-cutting innovation themes, including dementia, diabetes, musculoskeletal, alcohol and cancer. www.hin-southlondon.org 

 

Enquiries:

 

IXICO plc

Derek Hill, CEO

Charles Spicer, VP Corporate Development

+44 20 7691 2064

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel

Clare Terlouw

+44 20 7418 8900

 

Daniel Stewart & Company (Joint Broker)

Mark Treharne

David Hart

+44 207 776 6550

 

FTI Consulting Limited (Investor Relations)

Ben Atwell

Simon Conway

John Dineen

+44 20 3727 1000 

 

Health Innovation Network

Anna King, Commercial Director

+44 20 7188 7188

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASFDEDIFLSEFL
Date   Source Headline
8th Feb 202212:30 pmRNSHolding(s) in Company
8th Feb 20227:00 amRNSContract award worth circa £1.0m
31st Jan 20227:00 amRNSAppointment of Senior Therapeutic Advisor
26th Jan 20227:00 amRNSDementia collaboration
21st Jan 20227:00 amRNSNon-Executive Director Appointment
20th Jan 202210:50 amRNSResult of AGM
20th Jan 20227:00 amRNSHuntington’s disease contract update
10th Jan 20227:00 amRNSGrant of share options
7th Dec 20217:00 amRNSFinancial Results for the year ended 30 Sept 2021
22nd Nov 20217:00 amRNSNotice of Results
1st Nov 20216:08 pmRNSHolding(s) in Company
1st Nov 20217:00 amRNSNew contract worth >£1.0m
20th Oct 20214:27 pmRNSContract update
18th Oct 20217:00 amRNSTrading Update for year ended 30 September 2021
22nd Sep 20217:00 amRNSNew contract worth >$750k
20th Sep 20217:00 amRNSPhase II HD contract with new client worth >$500K
8th Sep 20217:00 amRNSPhase I MSA contract award worth >$500k
6th Aug 20217:00 amRNSTrading Update
23rd Jun 20213:32 pmRNSIssue of Equity
21st Jun 20212:31 pmRNSHolding(s) in Company
15th Jun 20217:00 amRNSFurther investment in Ixico plc
11th Jun 202111:35 amRNSHolding(s) in Company
25th May 20217:00 amRNSHalf yearly report to 31 March 2021
20th May 20217:00 amRNSPhase II Alzheimer’s disease contract award
19th May 20217:00 amRNSContract win for new neuroinflammatory disorder
11th May 20217:00 amRNSNotice of results
28th Apr 20217:00 amRNSContract win for new stroke study
26th Apr 20217:00 amRNSTrading update
19th Apr 20218:21 amRNSHolding(s) in Company
12th Apr 20214:00 pmRNSHolding(s) in Company
12th Apr 20217:00 amRNSInvestment in Ixico plc
1st Apr 20217:00 amRNSHolding(s) in Company
25th Mar 20219:14 amRNSPDMR Transaction
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:35 pmRNSPrice Monitoring Extension
23rd Mar 20213:05 pmRNSHuntington’s disease Phase III contract updates
15th Mar 20214:41 pmRNSSecond Price Monitoring Extn
15th Mar 20214:35 pmRNSPrice Monitoring Extension
15th Mar 20212:06 pmRNSSecond Price Monitoring Extn
15th Mar 20212:00 pmRNSPrice Monitoring Extension
15th Mar 202111:06 amRNSSecond Price Monitoring Extn
15th Mar 202111:01 amRNSPrice Monitoring Extension
15th Mar 20217:00 amRNSCollaboration with Microsoft
10th Mar 20217:00 amRNSIXICO chosen for new Phase II AD study
2nd Mar 20217:00 amRNSIXICO selected by Cyclerion for a new AD study
1st Mar 20215:25 pmRNSExercise of Options; PDMR Dealing
1st Mar 20217:00 amRNSConference attendance and presentations
29th Jan 202110:19 amRNSPDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.